Top

Supportive Care in Cancer

Published in:

01-01-2013 | Original Article

A prospective study of quality of life including fatigue and pulmonary function after stereotactic body radiotherapy for medically inoperable early-stage lung cancer

Authors: Gregory M. M. Videtic, Chandana A. Reddy, Lisa Sorenson

Published in: Supportive Care in Cancer | Issue 1/2013

Abstract

Purpose

The study seeks to prospectively evaluate pulmonary function and quality of life (QOL) in medically inoperable early-stage lung cancer patients undergoing stereotactic body radiotherapy (SBRT).

Methods

QOL was assessed by Functional Assessment of Cancer Therapy-Lung (FACT-L) and the UCSD Medical Center Pulmonary Rehabilitation Program Shortness-of-Breath Questionnaire before and after SBRT at 6 weeks, and every 3 months until 12 months. Clinical investigations included pulmonary functions tests and blood profile and chemistries. SBRT was delivered on a Novalis/BrainLab system.

Results

Twenty-one analyzable patients were enrolled between July 2008 to April 2009. There were 12 males (52.4 %), 14 patients (66.7 %) had Zubrod performance 1, the median age was 77 years (range 61–90), and 87 % was inoperable because of pulmonary impairment. Median tumor size was 3.0 cm (range 1–4.6). Median follow-up was 17.6 months. One-year local control was 100 %. There were no significant changes in the median total FACT-L scores: 109 at baseline compared to 112 at 1 year. Mean UCSD scores were not significant for the year. No significant changes in mean baseline compared to 1-year FEV1 and 6-min walks as % predicted were seen but a significant DLCO change (p = 0.012) was attributed to the decreased range in the standard deviations.

Conclusions

Following SBRT, QOL is not significantly degraded. Pulmonary function is likewise not significantly impaired overall. Along with favorable survival results, these findings confirm that SBRT is appropriate for this patient population.

Hansen HH (2009) Introduction. In: Hansen HH (ed) Lung Cancer Therapy Annual 6. Informa Health Care, New York, pp 1–6

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249PubMedCrossRef

Hansen HH (2009) Histopathology. In: Hansen HH (ed) Lung cancer therapy annual 6. Informa Health Care, New York, pp 45–56

Juettner-Smolle FM, Lindenmann J, Matzi V, Neubock N (2010) Resection in stage I/II non-small cell lung cancer. In: Heide J et al (eds) Controversies in the treatment of lung cancer. Karger, Basel, pp 71–77

Little AG, Rusch VW, Bonner JA, Gaspar LE, Green MR, Webb WR, Stewart AK (2005) Patterns of surgical care of lung cancer patients. Ann Thorac Surg 80:2051–2056PubMedCrossRef

Ginsberg RJ, Rubinstein LV (1995) Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 60:615–622PubMedCrossRef

Nyman J, Johansson KA, Hultén U (2006) Stereotactic hypofractionated radiotherapy for stage I non-small cell lung cancer—mature results for medically inoperable patients. Lung Cancer 51:97–103PubMedCrossRef

Lax I, Blomgren H, Näslund I, Svanström R (1994) Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects. Acta Oncol 33:677–683PubMedCrossRef

Stephans KL, Djemil T, Reddy CA et al (2009) A comparison of two stereotactic body radiation fractionation schedules for medically inoperable stage I non-small cell lung cancer: the Cleveland Clinic experience. J Thorac Oncol 4:976–982PubMedCrossRef

10.

Haasbeek CJ, Lagerwaard FJ, de Jaeger K, Slotman BJ, Senan S (2009) Outcomes of stereotactic radiotherapy for a new clinical stage I lung cancer arising postpneumonectomy. Cancer 115:587–594PubMedCrossRef

11.

Haasbeek CJ, Lagerwaard FJ, Antonisse ME, Slotman BJ, Senan S (2010) Stage I nonsmall cell lung cancer in patients aged > or =75 years: outcomes after stereotactic radiotherapy. Cancer 116:406–414PubMedCrossRef

12.

Hoopes DJ, Tann M, Fletcher JW, Forquer JA, Lin PF, Lo SS, Timmerman RD, McGarry RC (2007) FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer. Lung Cancer 56:229–234PubMedCrossRef

13.

Onishi H, Shirato H, Nagata Y et al (2007) Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2:S94–S100PubMedCrossRef

14.

Chang JY, Roth JA (2007) Stereotactic body radiation therapy for stage I non-small cell lung cancer. Thorac Surg Clin 17:251–259PubMedCrossRef

15.

Timmerman R, Papiez L, McGarry R et al (2003) Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest 124:1946–1955PubMedCrossRef

16.

Timmerman R, McGarry R, Yiannoutsos C et al (2006) Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 24:4833–4839PubMedCrossRef

17.

Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, Fakiris A, Bezjak A, Videtic G, Johnstone D, Fowler J, Gore E, Choy H (2010) Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303:1070–1076PubMedCrossRef

18.

Langendijk JA, Aaronson NK, de Jong JM, ten Velde GP, Muller MJ, Slotman BJ, Wouters EF (2002) Quality of life after curative radiotherapy in Stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 53:847–853PubMedCrossRef

19.

van der Voort van Zyp NC, Prévost JB, van der Holt B, Braat C, van Klaveren RJ, Pattynama PM, Levendag PC, Nuyttens JJ (2010) Quality of life after stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 77:31–37PubMedCrossRef

20.

Lung (2002) In: Greene FL et al. (eds) AJCC cancer staging handbook, 6th edn. Springer, New York, pp 191–204

21.

Videtic GM, Stephans K, Reddy C, Gajdos S, Kolar M, Clouser E, Djemil T (2010) Intensity-modulated radiotherapy-based stereotactic body radiotherapy for medically inoperable early-stage lung cancer: excellent local control. Int J Radiat Oncol Biol Phys 77:344–349PubMedCrossRef

22.

Stephans KL, Djemil T, Reddy CA et al (2009) Comprehensive analysis of pulmonary function test (PFT) changes after stereotactic body radiotherapy (SBRT) for stage I lung cancer in medically inoperable patients. J Thorac Oncol 4:838–844PubMedCrossRef

23.

Lagerwaard FJ, Haasbeek CJ, Smit EF, Slotman BJ, Senan S (2008) Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 70:685–692PubMedCrossRef

24.

Cella DF, Bonomi AE, Lloyd SR, Tulsky DS, Kaplan E, Bonomi P (1995) Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 12:199–220PubMedCrossRef

25.

Henoch I, Bergman B, Gustafsson M, Gaston-Johansson F, Danielson E (2007) The impact of symptoms, coping capacity, and social support on quality of life experience over time in patients with lung cancer. J Pain Symptom Manag 34:370–379CrossRef

26.

Eakin EG, Resnikoff PM, Prewitt LM, Ries AL, Kaplan RM (1998) Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire. University of California, San Diego. Chest 113:619–624PubMedCrossRef

27.

http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf, accessed January 2, 2011

28.

Mohan A, Mohan C, Pathak AK, Pandey RM, Guleria R (2007) Impact of chronic obstructive pulmonary disease on respiratory status and quality of life in newly diagnosed patients with lung cancer. Respirology 12:240–247PubMedCrossRef

29.

Lima LN, da Silva RA, Gross JL, Deheinzelin D, Negri EM (2009) Assessment of pulmonary function and quality of life in patients submitted to pulmonary resection for cancer. J Bras Pneumol 35:521–528PubMedCrossRef

30.

Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139–144PubMed

31.

Sorenson LM, Reddy C, Videtic G (2010) Lessons learned from a prospective study of quality of life in lung cancer patients undergoing stereotactic body radiotherapy: the earlier, the better! Int J Radiat Oncol Biol Phys 78(suppl):S608–S609CrossRef

Title: A prospective study of quality of life including fatigue and pulmonary function after stereotactic body radiotherapy for medically inoperable early-stage lung cancer
Authors: Gregory M. M. Videtic
Chandana A. Reddy
Lisa Sorenson
Publication date: 01-01-2013
Publisher: Springer-Verlag
Published in: Supportive Care in Cancer / Issue 1/2013
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-012-1513-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2013

Systematic review of agents for the management of gastrointestinal mucositis in cancer patients

Chemotherapy in patients with advanced pancreatic cancer: too close to death?

The English and Chinese versions of the five-level EuroQoL Group's five-dimension questionnaire (EQ-5D) were valid and reliable and provided comparable scores in Asian breast cancer patients

The impact of individual quality of life assessment on psychosocial attention in patients with chest malignancies: a randomized study

A cross-sectional study of constipation and laxative use in advanced cancer patients: insights for revision of current practice

Walking a mile in their shoes: anxiety and depression among partners and caregivers of cancer survivors at 6 and 12 months post-diagnosis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer